ARGENT BIOPHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21 GBX | +6.06% |
|
-.--% | -22.22% |
| 05-07 | Argent BioPharma Reports CFO Appointment | MT |
| 05-07 | Argent BioPharma shares begin trading on OTCQB Venture Market | AN |
| Sales 2022 | 4.73M 3.15M 247M | Sales 2023 | 3.39M 2.25M 177M | Capitalization | 16.75M 11.14M 875M |
|---|---|---|---|---|---|
| Net income 2022 | -20M -13.3M -1.04B | Net income 2023 | -20M -13.3M -1.04B | EV / Sales 2022 | 9.75 x |
| Net Debt 2022 | 2.47M 1.64M 129M | Net Debt 2023 | 9.51M 6.33M 497M | EV / Sales 2023 | 7.75 x |
| P/E ratio 2022 |
-2.02
x | P/E ratio 2023 |
-0.7
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 9.44% |
More Fundamentals
* Assessed data
More news
| 1 day | +6.06% | ||
| 1 month | -2.33% | ||
| 3 months | +7.69% | ||
| 6 months | -42.47% | ||
| Current year | -22.22% |
1 week
19.80
22.00
1 month
19.8023.00
Current year
17.0027.00
1 year
13.10400.00
3 years
13.103 950.00
5 years
13.109 300.00
10 years
13.109 300.00
| Managers | Title | Age | Since |
|---|---|---|---|
Roby Zomer
FOU | Founder | 44 | 20/10/05 |
Yifat Steuer
COO | Chief Operating Officer | 53 | 03/10/22 |
Nadya Lisovoder
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roby Zomer
FOU | Founder | 44 | 20/10/05 |
| Director/Board Member | - | 31/05/23 | |
Daniel Robinson
BRD | Director/Board Member | - | 11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 21 | +6.06% | 1,563 |
| 30/05/24 | 19.8 | -5.71% | 1,226 |
| 29/05/24 | 21 | -.--% | 6,849 |
| 28/05/24 | 21 | -.--% | 38 |
| 24/05/24 | 21 | -.--% | 162 |
Delayed Quote London S.E., May 31, 2024 at 04:35 pm
More quotes
Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.
Sector
Pharmaceuticals
Calendar
27/08/2024
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +37.29% | 6.02B | |
| -21.28% | 4.19B | |
| +4.52% | 3.25B | |
| -18.16% | 2.87B | |
| -7.70% | 2.37B | |
| +41.50% | 1.89B | |
| -4.05% | 1.58B | |
| -15.56% | 1.54B | |
| -14.62% | 1.5B |
- Stock Market
- Equities
- RGT Stock
- RGT Stock
